These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

260 related items for PubMed ID: 12847558

  • 1. A review of the properties of spiradoline: a potent and selective kappa-opioid receptor agonist.
    Wadenberg ML.
    CNS Drug Rev; 2003; 9(2):187-98. PubMed ID: 12847558
    [Abstract] [Full Text] [Related]

  • 2. Analgesic and mechanistic evaluation of spiradoline, a potent kappa opioid.
    Vonvoigtlander PF, Lewis RA.
    J Pharmacol Exp Ther; 1988 Jul; 246(1):259-62. PubMed ID: 2839665
    [Abstract] [Full Text] [Related]

  • 3. Effects of spiradoline mesylate, a selective kappa-opioid-receptor agonist, on the central dopamine system with relation to mouse locomotor activity and analgesia.
    Kunihara M, Ohyama M, Nakano M.
    Jpn J Pharmacol; 1993 Jul; 62(3):223-30. PubMed ID: 8411771
    [Abstract] [Full Text] [Related]

  • 4. Analgesic activity of spiradoline mesylate (U-62,066E), a kappa opioid agonist in mice.
    Kunihara M, Ohyama M, Nakano M, Hayashi S.
    Life Sci; 1989 Jul; 45(13):1191-8. PubMed ID: 2796604
    [Abstract] [Full Text] [Related]

  • 5. Effects of a kappa agonist, spiradoline mesylate (U62,066E), on activation and vaginocervical-stimulation produced analgesia in rats.
    Boyle TJ, Masuda T, Cunningham ST.
    Brain Res Bull; 2001 Jan 15; 54(2):213-8. PubMed ID: 11275411
    [Abstract] [Full Text] [Related]

  • 6. The effects of spiradoline (U-62066E), a kappa-opioid receptor agonist, on neuroendocrine function in man.
    Ur E, Wright DM, Bouloux PM, Grossman A.
    Br J Pharmacol; 1997 Mar 15; 120(5):781-4. PubMed ID: 9138682
    [Abstract] [Full Text] [Related]

  • 7. Bremazocine: a kappa-opioid agonist with potent analgesic and other pharmacologic properties.
    Dortch-Carnes J, Potter DE.
    CNS Drug Rev; 2005 Mar 15; 11(2):195-212. PubMed ID: 16007240
    [Abstract] [Full Text] [Related]

  • 8. Neuroendocrine and behavioral effects of the selective kappa agonist spiradoline in Tourette's syndrome: a pilot study.
    Chappell PB, Leckman JF, Scahill LD, Hardin MT, Anderson G, Cohen DJ.
    Psychiatry Res; 1993 Jun 15; 47(3):267-80. PubMed ID: 8396784
    [Abstract] [Full Text] [Related]

  • 9. Sodium channel-blocking properties of spiradoline, a kappa receptor agonist, are responsible for its antiarrhythmic action in the rat.
    Pugsley MK, Saint DA, Hayes ES, Kramer D, Walker MJ.
    J Cardiovasc Pharmacol; 1998 Dec 15; 32(6):863-74. PubMed ID: 9869491
    [Abstract] [Full Text] [Related]

  • 10. Central monoaminergic mechanisms in mice and analgesic activity of spiradoline mesylate, a selective kappa-opioid receptor agonist.
    Kunihara M, Ohyama M, Nakano M.
    Eur J Pharmacol; 1992 Apr 22; 214(2-3):111-8. PubMed ID: 1325350
    [Abstract] [Full Text] [Related]

  • 11. Intake of a palatable sucrose solution modifies the actions of spiradoline, a kappa opioid receptor agonist, on analgesia and feeding behavior in male and female rats.
    Kanarek RB, Homoleski BA, Wiatr C.
    Pharmacol Biochem Behav; 2000 Jan 01; 65(1):97-104. PubMed ID: 10638642
    [Abstract] [Full Text] [Related]

  • 12. Behavioral Characterization of κ Opioid Receptor Agonist Spiradoline and Cannabinoid Receptor Agonist CP55940 Mixtures in Rats.
    Minervini V, Dahal S, France CP.
    J Pharmacol Exp Ther; 2017 Feb 01; 360(2):280-287. PubMed ID: 27903642
    [Abstract] [Full Text] [Related]

  • 13. A pharmacological profile of the novel, peripherally-selective kappa-opioid receptor agonist, EMD 61753.
    Barber A, Bartoszyk GD, Bender HM, Gottschlich R, Greiner HE, Harting J, Mauler F, Minck KO, Murray RD, Simon M.
    Br J Pharmacol; 1994 Dec 01; 113(4):1317-27. PubMed ID: 7889287
    [Abstract] [Full Text] [Related]

  • 14. Cardiovascular depressant effects of the kappa opioid receptor agonists U50488H and spiradoline mesylate.
    Hall ED, Wolf DL, McCall RB.
    Circ Shock; 1988 Dec 01; 26(4):409-17. PubMed ID: 2850873
    [Abstract] [Full Text] [Related]

  • 15. Kappa opioid agonist-induced changes in IOP: correlation with 3H-NE release and cAMP accumulation.
    Moore TT, Potter DE.
    Exp Eye Res; 2001 Aug 01; 73(2):167-78. PubMed ID: 11446767
    [Abstract] [Full Text] [Related]

  • 16. Discriminative stimulus effects of spiradoline, a kappa-opioid agonist.
    Holtzman SG, Cook L, Steinfels GF.
    Psychopharmacology (Berl); 1991 Aug 01; 105(4):447-52. PubMed ID: 1663252
    [Abstract] [Full Text] [Related]

  • 17. Analgesic and discriminative stimulus properties of U-62,066E, the selective kappa-opioid receptor agonist, in the rat.
    Ohno M, Yamamoto T, Ueki S.
    Psychopharmacology (Berl); 1992 Aug 01; 106(1):31-8. PubMed ID: 1346721
    [Abstract] [Full Text] [Related]

  • 18. Modulatory effects of dopamine D3/2 agonists on kappa opioid-induced antinociception and diuresis in the rat.
    Cook CD, Barrett AC, Syvanthong C, Picker MJ.
    Psychopharmacology (Berl); 2000 Sep 01; 152(1):14-23. PubMed ID: 11041311
    [Abstract] [Full Text] [Related]

  • 19. The influence of the kappa agonist-spiradoline (U62066E) on the analgesic activity of some opioids at the spinal level.
    Stachura Z, Herman ZS.
    Pol J Pharmacol; 1994 Sep 01; 46(1-2):37-41. PubMed ID: 7981769
    [Abstract] [Full Text] [Related]

  • 20. Additive antinociceptive effects of mixtures of the κ-opioid receptor agonist spiradoline and the cannabinoid receptor agonist CP55940 in rats.
    Maguire DR, France CP.
    Behav Pharmacol; 2016 Feb 01; 27(1):69-72. PubMed ID: 26292184
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.